Deconstruction of a Nutlin: Dissecting the Binding Determinants of a Potent Protein-Protein Interaction Inhibitor

被引:45
作者
Fry, David C. [1 ]
Wartchow, Charles [1 ]
Graves, Bradford [1 ]
Janson, Cheryl [1 ]
Lukacs, Christine [1 ]
Kammlott, Ursula [1 ]
Belunis, Charles [1 ]
Palme, Stefan [2 ]
Klein, Christian [3 ]
Vu, Binh [1 ]
机构
[1] Roche Res Ctr, Nutley, NJ 07110 USA
[2] Roche Diagnost GmbH, D-82377 Penzberg, Germany
[3] Roche Glycart AG, CH-8952 Schlieren, Switzerland
关键词
Nutlin; protein-protein interaction inhibitor; p53; MDM2; binding affinity; DRUG DISCOVERY; MDM2; P53; RG7112;
D O I
10.1021/ml400062c
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
Protein-protein interaction (PPI) systems represent a rich potential source of targets for drug discovery, but historically have proven to be difficult, particularly in the lead. identification stage. Application of the fragment-based approach may help toward success with this target class. To provide an example toward understanding the potential issues associated with such an application, we have deconstructed one of the best established protein-protein inhibitors, the Nutlin series that inhibits the interaction between MDM2 and p53, into fragments, and surveyed the resulting binding properties using heteronuclear single quantum coherence nuclear magnetic resonance (HSQC NMR), surface plasmon resonance (SPR), and X-ray crystallography. We report the relative contributions toward binding affinity for each key substituents of the Nutlin molecule and show that this series could hypothetically have been discovered via fragment approach. We find that the smallest fragment of Nutlin that retains binding accesses two subpockets of MDM2 and has a molecular weight at the high end of the range that normally defines fragments.
引用
收藏
页码:95 / 100
页数:6
相关论文
共 18 条
[1]
[Anonymous], 2010, Drug Discov Today Technol, V7, pe147, DOI 10.1016/j.ddtec.2010.11.003
[2]
Fragment-Based Deconstruction of Bcl-xL Inhibitors [J].
Barelier, Sarah ;
Pons, Julien ;
Marcillat, Olivier ;
Lancelin, Jean-Marc ;
Krimm, Isabelle .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) :2577-2588
[3]
Bower JF, 2012, CURR PHARM DESIGN, V18, P4685
[4]
Fry D. C., 2013, PROTEIN PROTEIN INTE
[5]
Fry DC, 2012, PROTEIN PROTEIN INTE, P55
[6]
Fragment-based drug design: How big is too big? [J].
Hajduk, Philip J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (24) :6972-6976
[7]
Ligand efficiency: a useful metric for lead selection [J].
Hopkins, AL ;
Groom, CR ;
Alex, A .
DRUG DISCOVERY TODAY, 2004, 9 (10) :430-431
[8]
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain [J].
Kussie, PH ;
Gorina, S ;
Marechal, V ;
Elenbaas, B ;
Moreau, J ;
Levine, AJ ;
Pavletich, NP .
SCIENCE, 1996, 274 (5289) :948-953
[9]
Murray CW, 2009, NAT CHEM, V1, P187, DOI [10.1038/NCHEM.217, 10.1038/nchem.217]
[10]
PICKSLEY SM, 1994, ONCOGENE, V9, P2523